Ratg

Leukemia, Acute

Everett MeyerPhase 1/2Dormant

C

36/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 21/ 100
Competitive Position: 89/ 100

Competitive context

60 Active assets in the Leukemia, Acute cohort.

Asset / Sponsor	Phase	Rating
Fludarabine Sawa Ito, MD	Phase 2/3	BB
Cyclophosphamide Sawa Ito, MD	Phase 4	BB
Cytosin-Arabinosid Janssen Research & Development, LLC	Phase 2/3	BB
ETOPOSIDE Nanfang Hospital, Southern Medical University	Phase 2/3	BB
Busulphan Sawa Ito, MD	Phase 4	BB

View all 50 →

Same molecule, other indications

Ratg is also rated in:

Acute Myelogenous LeukemiaDormant

CCC

Indicative ·

51 / 100

Myelodysplastic SyndromeDormant

CCC

Indicative ·

48 / 100

Chronic Myelogenous LeukemiaDormant

CC

Indicative ·

47 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.